Trinity Biotech (TRIB) Long-Term Deferred Tax (2016 - 2024)
Trinity Biotech (TRIB) has disclosed Long-Term Deferred Tax for 9 consecutive years, with $3.6 million as the latest value for Q4 2024.
- Quarterly Long-Term Deferred Tax rose 79.9% to $3.6 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Dec 2024, up 79.9% year-over-year, with the annual reading at $3.6 million for FY2024, 79.9% up from the prior year.
- Long-Term Deferred Tax hit $3.6 million in Q4 2024 for Trinity Biotech, up from $2.0 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $4.2 million in Q4 2022 to a low of $2.0 million in Q4 2023.
- Historically, Long-Term Deferred Tax has averaged $3.6 million across 5 years, with a median of $4.1 million in 2021.
- Biggest five-year swings in Long-Term Deferred Tax: crashed 53.18% in 2023 and later surged 79.9% in 2024.
- Year by year, Long-Term Deferred Tax stood at $4.2 million in 2020, then fell by 2.01% to $4.1 million in 2021, then grew by 2.85% to $4.2 million in 2022, then plummeted by 53.18% to $2.0 million in 2023, then skyrocketed by 79.9% to $3.6 million in 2024.
- Business Quant data shows Long-Term Deferred Tax for TRIB at $3.6 million in Q4 2024, $2.0 million in Q4 2023, and $4.2 million in Q4 2022.